A Review of Selected Federal Vaccine and Immunization Policies, Based on Case Studies of Pneumococcal Vaccine

September 1979

NTIS order #PB80-116106
FOREWORD

This work originated in April 1978 as a background study in OTA’S Congressional Fellowship Program. The study initially was limited to an analysis of the benefits and costs of pneumococcal vaccine, with particular emphasis on vaccine reimbursement under Medicare for the elderly. As a result of encouragement by several reviewers, the scope of investigation was broadened substantially to include three other areas of vaccine policy concerns: research, development, and production; safety and efficacy; and liability. Cost-effectiveness analysis was selected to assess benefits and costs, and the entire report was incorporated into a larger OTA study entitled Cost-Effectiveness of Medical Technologies. This report is the first of six documents to be published as a part of the larger cost-effectiveness study.

A Review of Selected Federal Vaccine and Immunization Policies was prepared by OTA staff in consultation with several authorities in the relevant subject areas. The authors’ professional backgrounds include training in public health, pharmacy, economics, law, medicine, public administration, public policy, and political science. Consultants included representatives from pharmaceutical companies, including Eli Lilly and Company, Merck Sharp and Dohme, and Lederle Laboratories; Government agencies, including the Bureau of Biologics (BOB), Center for Disease Control (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Center for Health Statistics (NCHS), and Bureau of the Census; and academic institutions, in particular, Duke University, Harvard University, the University of Pennsylvania, and the University of California at San Francisco.

Drafts of the report were reviewed by members of two OTA advisory bodies: the Health Program Advisory Committee and the Cost-Effectiveness of Medical Technologies Advisory Panel. Various drafts also were reviewed by approximately 50 other individuals representing a wide range of professional disciplines. We were grateful for these many contributions to the work.

JOHN H. GIBBONS
Director
OTA HEALTH GROUP STAFF

Joyce C. Lashof, Assistant Director
Health and Life Sciences Division

H. David Banta, Health Group Manager

Michael A. Riddough, Project Director

Jane Sisk Willems, Health Economics and Policy
Co-Project Director (April-September 1978)

Claudia Sanders, Health Policy

Lawrence Miike, Vaccine Liability

John Bell, Computer Modeling

Clyde Behney, Health Policy

Editorial Staff

Kerry B. Kemp, Editor and Writer

Page S. Gardner, Editor

Administrative Staff

Virginia Cwolina
Shirley Ann Gayheart
William S. Burnett

OTA PUBLISHING STAFF

John C. Holmes, Publishing Officer

Kathie S. Boss
Joanne Heming

*Independent contractor
OTA HEALTH GROUP ADVISORY COMMITTEE

Frederick C. Robbins, Chairman
Dean, School of Medicine, Case Western Reserve University

Stuart H. Altman
Dean
Florence Heller School
Brandeis University

Robert M. Ball
Senior Scholar
Institute of Medicine
National Academy of Sciences

Bernard Barber
Professor
Department of Sociology
Barnard College
Columbia University

Lewis H. Butler
Adjunct Professor of Health Policy
Health Policy Program
University of California

Kurt Deuschle
Professor of Community Medicine
Mount Sinai School of Medicine

Rashi Fein
Professor of the Economics of Medicine
Center for Community Health and Medical Care
Harvard Medical School

Melvin A. Glasser
Director
Social Security Department
United Auto Workers

Sidney S. Lee
Associate Dean
Community Medicine
McGill University

Mark Lepper
Vice President for Evaluation
Rush-Presbyterian Medical School
St. Luke's Medical Center

C. Frederick Mosteller
Professor and Chairman
Department of Biostatistics
School of Public Health
Harvard University

Beverlee Myers
Director
Department of Health Services
State of California

Helen Ewing Nelson
President
Consumer Research Foundation
Mill Valley, Calif.

Charles A. Sanders
General Director
Massachusetts General Hospital

Kerr L. White
Deputy Director of Health Sciences
Rockefeller Foundation
COST-EFFECTIVENESS OF MEDICAL TECHNOLOGIES
ADVISORY PANEL MEMBERS

John R. Hogness, Chairman
President, Association for Academic Health Centers

Stuart H. Altman
Dean
Florence Heller School
Brandeis University

James L. Bennington
Chairman
Department of Anatomic Pathology and Clinical Laboratories
Children's Hospital
San Francisco, Calif.

John Chase
Associate Dean for Clinical Affairs
University of Washington School of Medicine

Joseph Fletcher
Visiting Scholar
Medical Ethics
School of Medicine
University of Virginia

Clark C. Havighurst
Professor of Law
School of Law
Duke University

Sheldon Leonard
Manager
Regulatory Affairs
General Electric Company

Barbara J. McNeil
Department of Radiology
Peter Bent Brigham Hospital

Robert H. Moser
Executive Vice President
American College of Physicians

C. Frederick Mosteller
Chairman
Department of Biostatistics
Harvard University

Robert M. Sigmond
Advisor in Hospital Affairs
Blue Cross and Blue Shield Associates

Jane Sisk Willems
V.A. Scholar
Veterans Administration
ACKNOWLEDGMENTS

Several people provided valuable assistance in the preparation of this report. Individuals at the National Center for Health Statistics (NCHS), in particular, were very instrumental in developing data sets for the cost-effectiveness analysis. While OTA must assume ultimate responsibility for the content of this report, it greatly appreciates the contributions of—among many others—the following individuals:

Clarence A. Abramson  
Senior Counsel  
Merck and Company, Inc.  
Rahway, N.J.

Robert Austrian, M.D.  
Department of Research Medicine  
University of Pennsylvania  
School of Medicine  

Michael Beatrice, R. Ph., M.S.  
Bureau of Biologics  
Food and Drug Administration  
Bethesda, Md.

Claire Broome, M.D.  
Center for Disease Control  
Atlanta, Ga.

David W. Fraser, M. D.,  
Center for Disease Control  
Atlanta, Ga.

Donald Hill  
Bureau of Biologics  
Food and Drug Administration  
Bethesda, Md.

James Hill, Ph.D.  
National Institute of Allergy and Infectious Diseases  
Bethesda, Md.

Maurice Hilleman, Ph. D., D. SC.  
Director  
Merck Institute for Therapeutic Research  
West Point, Pa.

Alan R. Hinman, M. D., M.P.H.  
Center for Disease Control  
Atlanta, Ga.

Mark Hornbrook, Ph.D.  
National Center for Health Services Research  
Hyattsville, Md.

Irving S. Johnson, Ph.D.  
Vice President of Research  
Eli Lilly and Company  
Indianapolis, Ind.

Joel Kavet, D. SC.  
Department of Health, Education, and Welfare  
Rockville, Md.

Kenneth Manton, Ph.D.  
Duke University  
Durham, N.C.

Barbara J. McNeil, M. D., Ph.D.  
Harvard Medical School  
Boston, Mass.

Harry M. Meyer, Jr., M.D.  
Director  
Bureau of Biologics  
Food and Drug Administration  
Bethesda, Md.

Elena Nightingale, M.D.  
Institute of Medicine  
Washington, D.C.

Paul D. Parkman, M.D.  
Deputy Director  
Bureau of Biologics  
Food and Drug Administration  
Bethesda, Md.

Frederick C. Robbins, M.D.  
Dean, School of Medicine  
Case Western Reserve University  
Cleveland, Ohio

John Robbins, M.D.  
Bureau of Biologics  
Food and Drug Administration  
Bethesda, Md.

Donald Shepard, Ph.D.  
Harvard School of Public Health  
Boston, Mass.

Eric Stollard  
Duke University  
Durham, N.C.

Judith Wagner, Ph.D.  
Urban Institute  
Washington, D.C.

Ronald Wilson  
National Center for Health Statistics  
Department of Health, Education, and Welfare  
Hyattsville, Md.